9887 Share Price Performance
HK$88.95
21.85 (32.56%)
Price HK$88.95
Share Pricen/a
Nanjing Leads Biolabs Co., Ltd. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
9887 Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Nanjing Leads Biolabs Co., Ltd. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -1.07
- 100.00%
- -119.27%
- 20.5%
About 9887
- Founded
- 2012
- Employees
- 192
- CEO
- WebsiteView website
Nanjing Leads Biolabs Co., Ltd., a clinical-stage biotechnology company, engages in the research, development, and commercialisation of novel antibody drugs worldwide. It develops therapies in oncology, autoimmune, and other severe diseases. The company’s lead product LBL-024, a PD-L1/4-1BB bispecific antibody for extra-pulmonary neuroendocrine carcinoma, as well as LBL-034, LBL-033, and LBL-007. In addition, it develops LeadsBody platform, a portfolio of CD3 T-cell engagers that demonstrate anti-tumor efficacy and safety in preclinical/clinical studies; X-body platform, a 4-1BB/PD-L1 bispecific antibody. The company also develops antibody drugs for anti-tumor, autoimmune and infectious diseases and establishes tumor immunoassay. The company was founded in 2012 and is headquartered in Nanjing, China.
